Omnicell, Inc. — FY2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. The filing also reports unaudited fourth-quarter results. Omnicell provides automated medication and medical-supply management systems, software, analytics, and related services, primarily to hospitals in the United States and Canada.
Financial performance and liquidity
| Metric | FY2011 | FY2010 |
|---|---|---|
| Revenue | $245.5 million | $222.4 million |
| Gross profit / margin | $135.8 million / 55.3% | $117.9 million / 53.0% |
| Operating income / margin | $16.2 million / 6.6% | $9.5 million / 4.3% |
| Net income | $10.4 million | $4.9 million |
| Diluted EPS | $0.30 | $0.15 |
| Net cash from operating activities | $31.2 million | $20.6 million |
| Cash and cash equivalents plus short-term investments, year-end | $199.9 million | $183.7 million |
| Total assets / stockholders’ equity, year-end | $362.1 million / $282.9 million | $343.2 million / $265.2 million |
Fourth quarter: Revenue was $62.9 million, gross profit $35.9 million, operating income $6.2 million, and net income $4.1 million. In Q4 2010, these were $57.3 million, $31.4 million, $1.5 million, and $0.7 million, respectively. Q4 2011 gross margin was approximately 57.0%.
Debt and liquidity: The filing does not identify conventional borrowings as a material source of financing. Total liabilities were $79.2 million, including deferred service revenue and deferred gross profit; long-term obligations were reported as $20.3 million and were principally deferred service revenue. Current assets were $281.8 million versus current liabilities of $58.9 million. Management said existing liquidity and expected operating cash flows should fund working capital, capital expenditures, acquisitions, and contractual obligations for at least the next 12 months. No off-balance-sheet arrangements were reported.
Changes versus prior comparable periods
- FY2011 revenue rose 10.4%; product revenue grew 8.6% and service and other revenue grew 16.3%, the latter reflecting a larger installed base and more service contracts.
- Gross margin increased 2.3 percentage points. Management cited favorable product mix, lease renewals, manufacturing efficiencies, cost reductions, and service growth.
- Operating expenses rose 10.3%, led by a 13.1% increase in selling, general and administrative expense, including additional sales and marketing staffing and a $1.0 million Medacist settlement charge. No restructuring charges were recorded in 2011, compared with $1.2 million in 2010.
- Operating cash flow increased by $10.6 million. Inventory rose $9.4 million, primarily to support the G4 product launch; share repurchases used $12.6 million.
- Backlog increased to $133.9 million from $126.8 million at year-end 2010. The company cautioned that backlog may change with customer configurations and installation schedules.
Outlook, risks, and notable items
- Management projected FY2012 revenue growth of approximately 7%–8%, expected service revenue and associated gross profit to continue increasing, and anticipated positive operating cash flow. It expected research and development expense to increase slightly and SG&A as a percentage of revenue to stabilize and decline.
- The G4 automation platform and related product launches were important growth initiatives. Early G4 production carried higher costs during ramp-up; management expected future product costs to become more comparable to the prior generation, subject to product mix.
- Key risks include hospital capital-budget constraints and long sales/install cycles; competition and pricing pressure; delays in installation and revenue recognition; product acceptance, performance, and integration with customer systems; dependence on certain suppliers; and execution of international expansion.
- The company entered a 10-year lease for a new Mountain View headquarters, expected to commence in November 2012, with approximately $40 million in base lease commitments. Total operating lease and supplier commitments were $47.4 million at year-end.
- The Medacist litigation was settled for $1.0 million in exchange for a perpetual license; a further $0.5 million transfer fee may be due if specified change-in-control conditions occur. The filing reports no material liability recorded for general indemnification obligations.
- Management said a material weakness in income-tax accounting controls identified at year-end 2010 was remediated; management and the auditor concluded internal control over financial reporting was effective at December 31, 2011. The financial statement audit opinion was unqualified.
- Federal and California tax authorities were auditing tax years 2008 and 2009. Gross unrecognized tax benefits were $5.8 million; the filing stated no material change was expected over the next 12 months. Interest-rate exposure was described as immaterial.
- The company repurchased $12.6 million of shares during 2011 and had $12.4 million remaining under authorized repurchase programs at year-end. It had never paid cash dividends and did not anticipate doing so in the foreseeable future.
Investor verification priorities
- Confirm that the 7%–8% FY2012 revenue-growth outlook and expected service growth are supported by installation capacity, customer demand, and backlog conversion.
- Track gross-margin sustainability as G4 production scales and assess whether inventory growth creates obsolescence or working-capital risk.
- Review cash-flow generation alongside repurchases, capital spending, the new headquarters lease, and any acquisitions.
- Examine tax-audit outcomes, the $5.8 million of unrecognized tax benefits, and continued effectiveness of the remediated tax controls.
- Verify the terms and potential trigger for the additional $0.5 million Medacist transfer fee, and monitor any further litigation or contingency disclosures.